POZEN Inc. (POZN.O)
5.81USD
4:00pm EST
$-0.01 (-0.17%)
$5.82
$5.87
$5.91
$5.71
71,575
125,729
$8.42
$4.50
POZN.O
About
Overall
| Beta: | 1.23 |
| Market Cap (Mil.): | $173.58 |
| Shares Outstanding (Mil.): | 29.83 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| POZN.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.55 | 4.61 |
| EPS (TTM): | 20.54 | -- | -- |
| ROI: | -12.02 | 1.82 | 2.82 |
| ROE: | -13.56 | 2.44 | 4.12 |
CORRECTED - CORRECTED-(Aug 31)-UPDATE 1-Pozen says FDA accepts Vimovo NDA
(Corrects second paragraph in Aug. 31 story to clarify the drug Vimovo contains an immediate release form of AstraZeneca's esomeprazole, not the enteric-coated formulation found in Nexium)
HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 31
(Updates to afternoon trading, adds Whirlpool, ProLogis, GEO Group, Pozen, KKR Financial and Sequenom)
UPDATE 1-Pozen says US FDA accepts Vimovo marketing application
Aug 31 (Reuters) - Pozen Inc said U.S. health regulators have accepted a marketing application for its experimental pain drug Vimovo, triggering a $10 million milestone payment from AstraZeneca to Pozen.
HEADLINE STOCKS-Some U.S. stocks on the move on July 28
(Updates to add GE, U.S. Steel, Valero, Jacobs Engineering, MetLife, Harsco, Sonic Automotive, AMB Property, Alliance Resources, Paccar, Roper, Amcore, Tenet, Vishay, Supervalu, Ecolabs, Pozen, Ceradyne and Energizer)
UPDATE 1-Pozen swings to Q2 loss as licensing rev slumps
July 28 (Reuters) - Pharmaceutical company Pozen Inc posted an 84 percent slump in its licensing revenue, as it swung to a quarterly loss that scarped in ahead of market expectations.
FTSE off 1 percent on weak U.S. data
LONDON (Reuters) - The top share index shed 1 percent on Tuesday in the wake of weaker than expected consumer confidence figures in the United States, with banks, miners and food retailers leading the fallers.
FTSE off 1 percent on weak U.S. data
LONDON (Reuters) - The top share index shed 1 percent on Tuesday in the wake of weaker than expected consumer confidence figures in the United States, with banks, miners and food retailers leading the fallers.
RPT-FTSE off 1 pct on weak U.S. data, oils drag
* Oils fall with crude price decline on weakening demand
UPDATE 2-Astra, Pozen seek U.S. approval for new pain drug
* AstraZeneca to make $10 mln milestone payment to Pozen
UPDATE 1-Pozen posts narrower-than-expected Q4 loss
* Revenue more than doubles to $14.0 mln vs est $10.4 mln
Competitors
| Price | Change | |
|---|---|---|
| GlaxoSmithKline plc (GSK.L) | £1,303.00 | +5.00 |
| Merck & Co., Inc. (MRK.N) | $37.07 | -0.09 |
| AstraZeneca plc (AZN.L) | £2,823.00 | +27.00 |
| Johnson & Johnson (JNJ.N) | $64.85 | +0.08 |
| Pfizer Inc. (PFE.N) | $18.30 | -0.02 |
| Endo Pharmaceuticals (ENDP.OQ) | $19.85 | +0.12 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
